#Ireland #Dublin #Cardiac Imaging #LUMA Vision #VERAFEYE System

LUMA Vision to Present VERAFEYE System at AF Symposium

LUMA Vision Ltd., an innovator in cardiac technology, is set to highlight its state-of-the-art VERAFEYE™ System during the upcoming Atrial Fibrillation (AF) Symposium. Slated for February 6, 2026, the presentation will feature a recorded clinical case by Dr. Ante Anić, the Electrophysiology (EP) Lab Director at University Hospital Split. The demonstration will detail a clinical study aimed at evaluating the system's performance in real-world ablation workflows.

Dr. Anić has praised the VERAFEYE System, stating, "The performance during our initial 15-case series has been remarkable. Its capacity to quickly generate high-quality digital anatomy alongside real-time 2D visualization has significantly improved our procedural efficiency. I am eager to share our experience with the global community of electrophysiologists.”

The VERAFEYE System stands out with its AI-driven imaging and navigation capabilities, integrating high-resolution 2D and 4D intracardiac imaging. With the ability to create detailed digital anatomy of both atria from just a single right atrial acquisition, the platform offers a real-time, four-dimensional portrayal of the heart in motion. This functionality facilitates a smoother two-catheter ablation workflow, elevating the effectiveness and accuracy of a variety of cardiac procedures.

Key Features of the VERAFEYE System

LUMA Vision boasts several advanced features within the VERAFEYE system, including:

• - 2D and 4D imaging: Achieved from a single catheter, ensuring comprehensive cardiac views.
• - Rapid anatomical modeling: Offers CT-quality anatomical models in around 60 seconds from a central right atrial position.
• - Digital steering: Enables seamless management of both 2D and 4D imaging outputs.
• - Automated catheter tracking: This feature maintains continuous contact confirmation, enhancing procedural safety.
• - Control capabilities: Users can manage all features from within the procedure field.
• - Tracking technology: Employs both magnetic and image-based tracking for heightened precision.

Fionn Lahart, CEO of LUMA Vision, expressed enthusiasm for the upcoming event, stating, “We are privileged to collaborate with Dr. Anić and his team in presenting this crucial clinical insight at such a significant venue. The VERAFEYE system signals a transformative evolution in electrophysiology imaging and navigation. Its ability to swiftly produce highly accurate digital anatomy and harness AI across various procedures positions us as a leader in future cardiac imaging solutions.”

Interestingly, it's important to note that the navigation features of the VERAFEYE System are not yet approved for commercial use. Nevertheless, LUMA Vision's commitment to innovation is evident, as they prepare for a broader U.S. market launch later this year, poised to redefine the standards of cardiac care.

About LUMA Vision

Headquartered in Dublin, Ireland, LUMA Vision is a privately owned medical technology company, with significant operations in Munich, Germany. It focuses on designing and developing innovative cardiac visualization and navigation systems that empower healthcare professionals with enhanced precision in treatment. The company's flagship product, VERAFEYE™, is engineered to provide a real-time, 360-degree view of intracardiac structures, aiming to revolutionize procedural accuracy in electrophysiology as well as structural heart interventions. Founded by Fionn Lahart and Christoph Hennersperger, LUMA Vision remains dedicated to transforming cardiac care through technological advancements to improve patient outcomes and save lives. Visit LUMA Vision's website for further insights on their pioneering solutions.